Sellas Life Sciences Group Inc. has entered into a collaboration with IMPACT-AML, a European initiative focused on advancing treatments for acute myeloid leukemia (AML). Through this agreement, IMPACT-AML will conduct a clinical study of Sellas’ CDK9 inhibitor SLS009 in combination with azacitidine and venetoclax for newly diagnosed AML patients with high-risk features. The partnership enables Sellas to expand its clinical program into Europe, with U.S. patient enrollment expected to begin in the first quarter of 2026 and European enrollment anticipated in the second quarter of 2026, subject to regulatory approvals. This collaboration is expected to improve capital efficiency and broaden patient access as the SLS009 program advances.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624998-en) on January 14, 2026, and is solely responsible for the information contained therein.